Tumor-derived TGF-
Menée à partir d'échantillons sanguins et du liquide d'épanchements tumoraux prélevés sur des patients, cette étude met en évidence un mécanisme par lequel le facteur de croissance TGF-bêta sécrété par les cellules tumorales supprime, en inhibant la respiration mitochondriale, la production d'interféron-gamma par les lymphocytes T CD4+
Résumé en anglais
The cytokine TGF-β has both immune-suppressive and tumor-suppressive functions; thus, a better understanding of the cell-type specificity of the effects of TGF-β might improve therapeutic strategies that target it. Dimeloe et al. found that TGF-β from tumor effusions suppressed the antitumor activity of CD4+ T cells by inhibiting their production of the inflammatory cytokine IFN-γ. The effects of TGF-β were mediated by Smad proteins in the mitochondria, rather than in the nucleus, and led to decreased mitochondrial respiration. Indeed, direct inhibition of a mitochondrial electron transport chain complex in CD4+ T cells was sufficient to inhibit IFN-γ production. Thus, these data suggest that TGF-β targets T cell metabolism to suppress antitumor immunity.Transforming growth factor–β (TGF-β) is produced by tumors, and increased amounts of this cytokine in the tumor microenvironment and serum are associated with poor patient survival. TGF-β–mediated suppression of antitumor T cell responses contributes to tumor growth and survival. However, TGF-β also has tumor-suppressive activity; thus, dissecting cell type–specific molecular effects may inform therapeutic strategies targeting this cytokine. Here, using human peripheral and tumor-associated lymphocytes, we investigated how tumor-derived TGF-β suppresses a key antitumor function of CD4+ T cells, interferon-γ (IFN-γ) production. Suppression required the expression and phosphorylation of Smad proteins in the TGF-β signaling pathway, but not their nuclear translocation, and depended on oxygen availability, suggesting a metabolic basis for these effects. Smad proteins were detected in the mitochondria of CD4+ T cells, where they were phosphorylated upon treatment with TGF-β. Phosphorylated Smad proteins were also detected in the mitochondria of isolated tumor-associated lymphocytes. TGF-β substantially impaired the ATP-coupled respiration of CD4+ T cells and specifically inhibited mitochondrial complex V (ATP synthase) activity. Last, inhibition of ATP synthase alone was sufficient to impair IFN-γ production by CD4+ T cells. These results, which have implications for human antitumor immunity, suggest that TGF-β targets T cell metabolism directly, thus diminishing T cell function through metabolic paralysis.
